Outcomes in Extensive-Stage Small Cell Lung Cancer Based on Trial Eligibility
A prospective cohort study compared outcomes for patients with extensive-stage small cell lung cancer who were trial eligible and those were trial ineligible.
Diagnosis & Disease Information
Cancer Patients May Be Treated With Drugs That Provide No Benefit
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Treatment for Relapsed SCLC Remains “Area of High Unmet Need”
Researchers found a lack of promising investigational treatments in late-stage development for SCLC in the second-line setting and beyond.
Hippocampal-Sparing PCI ‘Should Be Standard Care’ for Small-Cell Lung Cancer
Sparing the hippocampus did not increase the risk of brain metastasis.
Surgical Treatment of Spinal Cord Compression Caused by Metastatic Small Cell Lung Cancer: Ten Years of Experience in a Single Center
[Cancer Management and Research] A retrospective review of 30 patients who underwent resection of spinal tumor caused by metastatic SCLC demonstrated that surgery was critical to improving patients QOL and performance status.
Zepzelca Approved for Metastatic Small Cell Lung Cancer
The FDA has approved Zepzelca™ (lurbinectedin; Jazz Pharmaceuticals) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Need for PCI Questioned in Limited-Stage SCLC
Use of PCI after thoracic radiation did not improve survival.
FDA Approves Imfinzi for Extensive-Stage Small Cell Lung Cancer
The approval was based on data from the CASPIAN study, an active-controlled, open-label trial that investigated the combination of durvalumab plus chemotherapy vs chemotherapy alone.
Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
[Lung Cancer: Targets and Therapy] A review of the available data on lurbinectedin, a novel RNA-polymerase-II inhibitor that has shown promise as a single agent or in combination with chemotherapy in the second-line treatment of small-cell lung cancer.
Lurbinectedin Under Review for Relapsed Small Cell Lung Cancer
Lurbinectedin is a selective inhibitor of trans-activated RNA polymerase II transcription.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...